Search Within

Olivia Heffernan

Formats
  1. Meeting Abstract (5)
  2. Journal Article (1)
Groups
  1. Biostatistics Service (6)
  2. Center for Pancreatic Cancer Research (6)
  3. Department of Medicine (6)
  4. Epidemiology and Biostatistics (6)
  5. Gastrointestinal Oncology Service (6)
  6. Solid Tumor Oncology Division (6)

More Groups

People
  1. Joanne Chou (6)
  2. Marinela Capanu (6)
  3. Diane Reidy (5)
  4. Haley Hauser (5)
  5. Nitya Raj (5)
  6. Tiffany Le (5)

More People

Years
  1. 2022 (5)
  2. 2021 (1)
Publications
  1. Journal of Clinical Oncology (3)
  2. Pancreas (2)
  3. JCO Oncology Practice (1)
Publishers
  1. American Society of Clinical Oncology (4)
  2. Lippincott Williams & Wilkins (2)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment response and clinical outcomes of neuroendocrine neoplasms (NENs) treated with immune checkpoint inhibitors (ICIs): A single institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy-Lagunes, D.; Raj, N.
    Pancreas (2022)

    Fulltext@MSK | Save
  • Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well- differentiated neuroendocrine tumors (WDNETs)
    Meeting Abstract

    Raj, N.; Cruz, E.; Chou, J.; Capanu, M.; DeMore, A.; Hauser, H.; Heffernan, O.; Le, T.; Saltz, L.; Reidy-Lagunes, D.
    Pancreas (2022)

    Fulltext@MSK | Save
  • A randomized trial evaluating patient experience and preference between octreotide long-acting release and lanreotide for treatment of well-differentiated neuroendocrine tumors
    Journal Article

    Raj, N.; Cruz, E.; O'Shaughnessy, S.; Calderon, C.; Chou, J. F.; Capanu, M.; Heffernan, O.; DeMore, A.; Punn, S.; Le, T.; more...
    JCO Oncology Practice (2022)

    Fulltext@MSK | Save
  • Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy, D. L.; Raj, N. P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Randomized blinded study comparing injection site pain from octreotide long-acting-release (LAR) versus lanreotide during the treatment of well differentiated neuroendocrine tumors (WDNETs)
    Meeting Abstract

    Raj, N. P.; Cruz, E.; Chou, J. F.; Capanu, M.; Heffernan, O.; Le, T.; Hauser, H.; Saltz, L. B.; Reidy, D. L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save